Navigation Links
KaloBios Announces Preliminary Phase 1 Results in Advanced Hematologic Malignancies with KB004, an Anti-EphA3 Monoclonal Antibody
Date:12/10/2013

SOUTH SAN FRANCISCO, Calif., Dec. 10, 2013 /PRNewswire/ -- KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today announced preliminary results of an ongoing multi-center Phase 1 study of KB004, an anti-EphA3 monoclonal antibody (mAb), which the company is developing as a treatment for hematologic malignancies. Forty-four patients with refractory disease or who were unfit for chemotherapy have been enrolled in the dose escalation portion of the study.  The experimental patient-targeted therapeutic has been well tolerated, with initial evidence of clinical activity.

(Logo: http://photos.prnewswire.com/prnh/20130225/MM66380LOGO)

Preliminary results of the study were presented yesterday by lead investigator, Jeffrey E. Lancet, M.D. of the H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida at the 55th American Society of Hematology Annual Meeting and Exhibition (ASH), held this week in New Orleans, Louisiana.

"We are encouraged by the results seen with KB004 to date, which has been well-tolerated at doses up to 190 mg, with mild to moderate transient infusion reactions the most common toxicity," said Dr. Lancet. "There are some signs of activity as well, including a patient with relapsed acute myeloid leukemia (AML) who had sustained remission for over 1 year."

Escalating doses of KB004 were administered as a 1 or 2 hour infusion on days 1, 8, and 15 of a 21 day cycle at incremental doses of 20, 40, 70, 100, 140, 190 and 250 mg and will thereafter increase at 33% increments up to a planned maximum of 700 mg. The primary study objective is to determine a maximum tolerated dose, which has not yet been reached. Secondary objectives included evaluation of pharmacokinetics, imm
'/>"/>

SOURCE KaloBios Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology news :

1. KaloBios to Present KB004 Interim Phase 1 Clinical Data in Hematologic Malignancies at ASH
2. Wyss Institute at Harvard University announces election of 2 faculty to Natl Academy of Inventors
3. Reproductive Health Matters announces publication of its latest themed issue: New development paradigm
4. Afterburn Fuel Review Announces the Launch of its New and Informative Website
5. VaxTrac Announces Continued Support for Expansion of Biometric-based Mobile Vaccine Registry Programs in Benin
6. AIBS announces winners of Faces of Biology photo competition
7. NERC announces the winner of its first photo and essay competition
8. Elsevier announces the launch of open access journal: Current Plant Biology
9. AVS Announces Its Major Award Winners of 2013
10. The Association for Molecular Pathology announces highlights of Phoenix meeting
11. EMBO announces the launch of EMBO Press
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/10/2014)... on U.S. store shelves in early 2010, and people ... small packets can be tossed into a washing machine ... powder. The convenience, though, has come with risks for ... Nationwide Children,s Hospital found that from 2012 through 2013, ... younger than 6 years of age swallowing, inhaling, or ...
(Date:11/6/2014)... groundbreaking paper from a team of Florida State University ... plants could adapt to and survive environmental swings such ... the latest issue of the journal The Plant ... of DNA and proteins) is organized in a cell ... genes are turned on and others are turned off. ...
(Date:11/5/2014)... of biology in the UTSA College of Sciences, ... selected to receive a two-year $300,00 National Science ... (EAGER). The funding supports President Obama,s BRAIN Initiative, ... new technology that will demystify complex brain processes. ... neuroscience are broken into the interactions of multiple ...
Breaking Biology News(10 mins):Study finds laundry detergent pods, serious poisoning risk for children 2Maize analysis yields whole new world of genetic science 2UTSA biology professor awarded $300,000 NSF grant for brain research 2UTSA biology professor awarded $300,000 NSF grant for brain research 3
... WORCESTER, MA Scientists at the University of Massachusetts ... piecing together the short DNA reads produced by next-generation ... genome sequences. Job Dekker, PhD, and colleagues have shown ... accurately by measuring the frequency of interactions between DNA ...
... great number of women experience depression or anxiety while ... mood disorders may lead to long-term emotional and behavioral ... the fetal environment has a strong influence on offspring ... exact mechanisms by which this occurs are not completely ...
... 2013, Cleveland: Cleveland Clinic researchers Richard A. Padgett, Ph.D., and ... American Association for the Advancement of Science (AAAS). This year,s ... & Notes section of the journal Science on ... Department of Molecular Genetics at the Lerner Research Institute, was ...
Cached Biology News:University Of Massachusetts Medical School scientists re-imagine how genomes are assembled 2University Of Massachusetts Medical School scientists re-imagine how genomes are assembled 32 Cleveland Clinic researchers honored for contribution to science 2
(Date:11/26/2014)... (PRWEB) November 26, 2014 The ... City’s award-winning technology innovation centers, announced today that ... closing on December 1st. “Do you have a ... so, I want to know about it. AccelerateBaltimore ... idea to product in just 13 weeks.” ...
(Date:11/26/2014)... Silicon Valley Electronic Data Capture (EDC) ... Alliance , provider of clinical research and data management ... addition to its CRO Partnership Program, Clinovo expands ... India. , “We have found Clinovo’s ClinCapture to ... platform which is both user friendly and easy to ...
(Date:11/26/2014)... 25, 2014 Miles Holder, formerly of ... Graphel Carbon Products team as Sales/Marketing Manager. Mr. Holder ... customer service for the graphite industry. , “We are ... team,” stated Dave Trinkley, VP of Market and Product ... of experience in the graphite industry, along with his ...
(Date:11/26/2014)... Theravalues Corporation est fier d,annoncer le lancement de ... Hi Europe 2014 (du 2 au 4 décembre à ... la plus biodisponible actuellement sur le marché, elle ... approuvés par les règlements européens. La ... racine de curcuma ( Curcuma longa ) qui ...
Breaking Biology Technology:AccelerateBaltimore Applications to Close in 6 Days 2AccelerateBaltimore Applications to Close in 6 Days 3RPM Alliance Joins Clinovo’s CRO Partnership Program, Further Strengthening Its Presence in Southern California and India 2Miles Holder Joins Graphel Corporation as Sales/Marketing Manager 2La curcumine présentant la plus haute biodisponibilité bientôt en vente en Europe 2La curcumine présentant la plus haute biodisponibilité bientôt en vente en Europe 3
... SAN DIEGO, Sept. 27, 2011 Verenium Corporation (Nasdaq: ... developing and commercializing high-performance enzymes, today announced that it ... an aggregate of $34.9 million in principal amount of ... repurchase of approximately $1.1 million in principal amount of ...
... Circassia Ltd, a specialty biopharmaceutical company focused ... results showing that its ToleroMune® hay fever vaccine ... on placebo.  The treatment was extremely well tolerated. ... phase II study conducted in 50 hay fever ...
... Chemical Engineering department and the Kavli institute of Delft ... electrons can move freely in layers of linked semiconductor ... will be very useful for the development of cheap ... their findings on Sunday 25 September on the website ...
Cached Biology Technology:Verenium Announces Debt Repurchase 2Verenium Announces Debt Repurchase 3Circassia's Hay Fever Treatment Improves Patients' Allergy Symptoms in Phase II Clinical Trial 2Circassia's Hay Fever Treatment Improves Patients' Allergy Symptoms in Phase II Clinical Trial 3TU Delft: cheap and efficient solar cell made possible by linked nanoparticles 2